| Phase 16 trials |
|
Phase 1
|
NCT07669077 |
Jun 2026 → Feb 2027 expected |
— |
Janssen Research & Development, LLC |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05827874 |
Apr → Oct 2023 |
— |
Janssen Research & Development, LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05151692 |
May → Sep 2022 |
— |
Janssen Research & Development, LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04973566 |
Aug 2021 → May 2022 |
— |
Janssen Research & Development, LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04848558 |
May 2021 → May 2022 |
— |
Janssen Research & Development, LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02828046 |
May 2016 → Aug 2017 |
— |
Momenta Pharmaceuticals, Inc. |
Completed
|
No outcome recorded
|
| Phase 29 trials |
|
Phase 2
|
NCT04883619 |
Jan 2026 → Feb 2028 |
lupus nephritis |
Janssen Research & Development, LLC |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT06028438 |
Aug 2023 → Aug 2024 |
rheumatoid arthritis |
Janssen Research & Development, LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05379634 |
Jul 2022 → Sep 2025 overdue |
idiopathic inflammatory myopathy |
Janssen Research & Development, LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04991753 |
Oct 2021 → Aug 2022 |
rheumatoid arthritis |
Janssen Research & Development, LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04968912 |
Sep 2021 → Oct 2023 |
Sjogren syndrome |
Janssen Research & Development, LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04882878 |
Aug 2021 → Apr 2024 |
systemic lupus erythematosus |
Janssen Research & Development, LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03896295 |
Aug 2019 → Dec 2020 |
generalized myasthenia gravis |
Momenta Pharmaceuticals, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03772587 |
Apr 2019 → Jun 2020 |
generalized myasthenia gravis |
Momenta Pharmaceuticals, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03842189 |
Apr 2018 → Aug 2024 |
fetal erythroblastosis |
Janssen Research & Development, LLC |
Completed
|
No outcome recorded
|
| Phase 2/33 trials |
|
Phase 2/3
|
NCT05327114 |
Sep 2022 → May 2027 expected |
chronic inflammatory demyelinating polyradiculoneuropathy |
Janssen Research & Development, LLC |
Recruiting
|
No outcome recorded
|
|
Phase 2/3
|
NCT05265273 |
Jul 2022 → Jun 2026 overdue |
myasthenia gravis |
Janssen Research & Development, LLC |
Recruiting
|
No outcome recorded
|
|
Phase 2/3
|
NCT04119050 |
Aug 2019 → Feb 2025 overdue |
autoimmune hemolytic anemia, warm type |
Janssen Research & Development, LLC |
Active not recruiting
|
No outcome recorded
|
| Phase 36 trials |
|
Phase 3
|
NCT07438496 |
Mar 2026 → Dec 2028 expected |
systemic lupus erythematosus |
Janssen Research & Development, LLC |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07217587 |
Jan 2026 → Sep 2027 expected |
generalized myasthenia gravis |
Janssen Research & Development, LLC |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06533098 |
Feb 2025 → Dec 2027 expected |
fetal and neonatal alloimmune thrombocytopenia |
Janssen Research & Development, LLC |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06741969 |
Dec 2024 → Jan 2028 expected |
Sjogren syndrome |
Janssen Research & Development, LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05912517 |
Dec 2023 → Aug 2027 expected |
fetal erythroblastosis |
Janssen Research & Development, LLC |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT04951622 |
Jul 2021 → Nov 2023 overdue |
myasthenia gravis |
Janssen Research & Development, LLC |
Recruiting
|
No outcome recorded
|
| Phase not stated1 trial |
| — |
NCT05221619 |
— |
autoimmune hemolytic anemia, warm type |
Janssen Research & Development, LLC |
Temporarily not available
|
No outcome recorded
|